December 4, 2017
Chordia President Hiroshi Miyake Chordia Therapeutics, a biotech established by six former researchers of Takeda Pharmaceutical, expects that its CDC-like kinase (CLK) inhibitor in the preclinical stage would have the potential to become a 100 billion yen-blockbuster, President Hiroshi Miyake...read more